A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder

Journal of Clinical Psychiatry

Volumn 73, Issue 5, 2012, Pages 654-660

  Williams, Jill M ^a   Anthenelli, Robert M ^b   Morris, Chad D ^c   Treadow, Joan ^d   Thompson, John R ^d   Yunis, Carla ^d   George, Tony P ^e  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VARENICLINE;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ANXIETY DISORDER; ARTICLE; BACKACHE; CARBON MONOXIDE BLOOD LEVEL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; INFECTION; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MOOD; MORNING DOSAGE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SMOKING CESSATION; SUICIDAL IDEATION; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 84861838749     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07522     Document Type: Article

References (39)

1. Syamlal G, Mazurek JM, Malarcher AM; Centers for Disease Control and Prevention (CDC). Current cigarette smoking prevalence among working adults - United States, 2004-2010. MMWR Morb Mortal Wkly Rep. 2011;60(38):1305-1309. PubMed
2. Williams JM, Gandhi KK, Lu SE, et al. Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette. Nicotine Tob Res. 2010;12(8):855-859. doi:10.1093/ntr/ntq102 PubMed
3. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2-3):135-157. doi:10.1016/j.schres.205.02.010 PubMed (Pubitemid 40812332)
4. Weinberger AH, Sacco KA, Creeden CL, et al. Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia. Schizophr Res. 2007; 91(1-3):217-225. doi:10.1016/j.schres.206.12.07 PubMed
5. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177(3):212-217. doi:10.192/bjp.17.3.212 PubMed
6. Kelly DL, McMahon RP, Wehring HJ, et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull. 2011; 37(4):832-838. doi:10.1093/schbul/sbp152 PubMed
7. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284(20):2606-2610. doi:10.101/jama.284.20.2606 PubMed
8. Covey LS, Hughes DC, Glassman AH, et al. Ever-smoking, quitting, and psychiatric disorders: evidence from the Durham, North Carolina, Epidemiologic Catchment Area. Tob Control. 1994;3(3):222-227. doi:10.136/tc.3.3.2
9. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157(11):1835-1842. doi:10.176/api.ajp.157.1.1835 PubMed
10. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebocontrolled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25(3):218-225. doi:10.1097/01.jcp. 0162802.54076.18 PubMed (Pubitemid 40685784)
11. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002; 52(1):53-61. doi:10.1016/S06-323(02)0139-2 PubMed (Pubitemid 34655556)
12. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2010;6(6):CD007253. PubMed
13. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48(10):3474-3477. doi:10.1021/jm05069n PubMed (Pubitemid 40664098)
14. Jorenby DE, Hays JT, Rigotti NA, et al; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):56-63. doi:10.101/jama.296.1.56 PubMed
15. Gonzales D, Rennard SI, Nides M, et al; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47-55. doi:10.101/jama.296.1.47 PubMed
16. Wu P, Wilson K, Dimoulas P, et al. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health. 2006;6(1):300. doi:10.186/1471-2458-6-30 PubMed
17. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2011;2(2):CD006103. PubMed
18. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008; 179(2):135-144. doi:10.1503/cmaj.070256 PubMed (Pubitemid 352020119)
19. Moore TJ, Glenmullen J, Furberg CD. Thoughts and acts of aggression/ violence toward others reported in association with varenicline. Ann Pharmacother. 2010;44(9):1389-1394. doi:10.1345/aph.1P172 PubMed
20. Hughes JR. Clinical significance of tobacco withdrawal. Nicotine Tob Res. 2006;8(2):153-156. doi:10.1080/1462050494856 PubMed (Pubitemid 43675071)
21. Yaworski D, Robinson J, Sareen J, et al. The relation between nicotine dependence and suicide attempts in the general population. Can J Psychiatry. 2011;56(3):161-170. PubMed
22. Tonstad S, Davies S, Flammer M, et al. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf. 2010;33(4):289-301. doi:10.2165/1319180-0-0 PubMed
23. Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ. 2009;339:b3805. doi:10.136/bmj.b3805 PubMed
24. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007;164(8):1269. doi:10.176/api.ajp.207.07020326 PubMed
25. Evins AE, Goff DC. Varenicline treatment for smokers with schizophrenia: a case series. J Clin Psychiatry. 2008;69(6):1016. doi:10.408/JCP.v69n0620a PubMed (Pubitemid 351944959)
26. Fatemi SH. Varenicline efficacy and tolerability in a subject with schizophrenia. Schizophr Res. 2008;103(1-3):328-329. doi:10.1016/j.schres.208. 05.02 PubMed
27. Anghelescu I. Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient. J Neuropsychiatry Clin Neurosci. 2009;21(1):102-103. doi:10.176/api.neuropsych.21.1.102 PubMed
28. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103(1):146-154. doi:10.1/j.1360-043.207.02083.x PubMed (Pubitemid 350233424)
29. Weiner E, Buchholz A, Coffay A, et al. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res. 2011;129(1):94-95. doi:10.1016/j.schres.201.02.03 PubMed
30. Smith RC, Lindenmayer JP, Davis JM, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2009;110(1-3):149-155. doi:10.1016/j.schres.209.02.01 PubMed
31. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry suppl. 1989; (7):59-67. PubMed
32. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
33. Biener L, Abrams DB. The Contemplation Ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol. 1991;10(5): 360-365. doi:10.1037/0278-613.10.5.360 PubMed
34. Fiore MC, Jaén CR, Baker TB, et al. Clinical Practice Guideline. Treating Tobacco Use and Dependence: 2008 Update. Rockville, MD: US Department of Health and Human Services; 2008.
35. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127. doi:10.1/j.1360-043.191. tb01879.x PubMed
36. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;45(S212):11-19. doi:10.1/j.160-047.1970.tb0206. x PubMed
37. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035-1043. doi:10.176/api.ajp.164.7.1035 PubMed (Pubitemid 47121392)
38. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
39. Glare P, Pereira G, Kristjanson LJ, et al. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer. 2004;12(6):432-440. doi:10.107/s0520-04-0629-y PubMed (Pubitemid 38797099)